ZA939621B - Protein named component B - Google Patents
Protein named component BInfo
- Publication number
- ZA939621B ZA939621B ZA939621A ZA939621A ZA939621B ZA 939621 B ZA939621 B ZA 939621B ZA 939621 A ZA939621 A ZA 939621A ZA 939621 A ZA939621 A ZA 939621A ZA 939621 B ZA939621 B ZA 939621B
- Authority
- ZA
- South Africa
- Prior art keywords
- pct
- named component
- protein named
- sec
- date
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM920919A IT1257184B (it) | 1992-12-22 | 1992-12-22 | Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA939621B true ZA939621B (en) | 1995-06-22 |
Family
ID=11401349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA939621A ZA939621B (en) | 1992-12-22 | 1993-12-22 | Protein named component B |
Country Status (19)
Country | Link |
---|---|
US (1) | US5908827A (fr) |
EP (1) | EP0675956B1 (fr) |
JP (1) | JP3025014B2 (fr) |
KR (1) | KR100193107B1 (fr) |
AT (1) | ATE236976T1 (fr) |
AU (1) | AU690093B2 (fr) |
CA (1) | CA2151156A1 (fr) |
DE (1) | DE69332861T2 (fr) |
DK (1) | DK0675956T3 (fr) |
ES (1) | ES2193152T3 (fr) |
FI (2) | FI114478B (fr) |
IL (1) | IL108149A (fr) |
IT (1) | IT1257184B (fr) |
NO (1) | NO315800B1 (fr) |
PT (1) | PT675956E (fr) |
RU (1) | RU2177480C2 (fr) |
UA (1) | UA46702C2 (fr) |
WO (1) | WO1994014959A1 (fr) |
ZA (1) | ZA939621B (fr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0895478T3 (da) * | 1996-04-24 | 2003-06-23 | Applied Research Systems | Bestanddel B som ardanner |
AU8536698A (en) * | 1997-06-09 | 1998-12-30 | Wolf-Georg Forssmann | Lus-1 human protein, its production and use |
AU765600B2 (en) * | 1998-07-09 | 2003-09-25 | Merck Serono Sa | Compound B as angiogenic agent in combination with human growth factors |
US6962700B1 (en) | 2000-09-13 | 2005-11-08 | Atopix Pharmaceuticals Corporation | Method of manufacturing immune globulin |
ES2359408T3 (es) | 2003-04-16 | 2011-05-23 | Merck Serono Sa | Uso de slurp-1 para tratar enfermedades relacionadas con la disfunción de receptores de acetilcolina. |
US7343581B2 (en) * | 2005-06-27 | 2008-03-11 | Tela Innovations, Inc. | Methods for creating primitive constructed standard cells |
US7590968B1 (en) | 2006-03-01 | 2009-09-15 | Tela Innovations, Inc. | Methods for risk-informed chip layout generation |
US7763534B2 (en) | 2007-10-26 | 2010-07-27 | Tela Innovations, Inc. | Methods, structures and designs for self-aligning local interconnects used in integrated circuits |
US8225261B2 (en) | 2006-03-09 | 2012-07-17 | Tela Innovations, Inc. | Methods for defining contact grid in dynamic array architecture |
US7943967B2 (en) | 2006-03-09 | 2011-05-17 | Tela Innovations, Inc. | Semiconductor device and associated layouts including diffusion contact placement restriction based on relation to linear conductive segments |
US8225239B2 (en) | 2006-03-09 | 2012-07-17 | Tela Innovations, Inc. | Methods for defining and utilizing sub-resolution features in linear topology |
US8839175B2 (en) | 2006-03-09 | 2014-09-16 | Tela Innovations, Inc. | Scalable meta-data objects |
US8245180B2 (en) | 2006-03-09 | 2012-08-14 | Tela Innovations, Inc. | Methods for defining and using co-optimized nanopatterns for integrated circuit design and apparatus implementing same |
US9563733B2 (en) | 2009-05-06 | 2017-02-07 | Tela Innovations, Inc. | Cell circuit and layout with linear finfet structures |
US9035359B2 (en) | 2006-03-09 | 2015-05-19 | Tela Innovations, Inc. | Semiconductor chip including region including linear-shaped conductive structures forming gate electrodes and having electrical connection areas arranged relative to inner region between transistors of different types and associated methods |
US7932545B2 (en) | 2006-03-09 | 2011-04-26 | Tela Innovations, Inc. | Semiconductor device and associated layouts including gate electrode level region having arrangement of six linear conductive segments with side-to-side spacing less than 360 nanometers |
US8541879B2 (en) | 2007-12-13 | 2013-09-24 | Tela Innovations, Inc. | Super-self-aligned contacts and method for making the same |
US8247846B2 (en) | 2006-03-09 | 2012-08-21 | Tela Innovations, Inc. | Oversized contacts and vias in semiconductor chip defined by linearly constrained topology |
US7917879B2 (en) * | 2007-08-02 | 2011-03-29 | Tela Innovations, Inc. | Semiconductor device with dynamic array section |
US9230910B2 (en) | 2006-03-09 | 2016-01-05 | Tela Innovations, Inc. | Oversized contacts and vias in layout defined by linearly constrained topology |
US9009641B2 (en) | 2006-03-09 | 2015-04-14 | Tela Innovations, Inc. | Circuits with linear finfet structures |
US8448102B2 (en) | 2006-03-09 | 2013-05-21 | Tela Innovations, Inc. | Optimizing layout of irregular structures in regular layout context |
US7446352B2 (en) | 2006-03-09 | 2008-11-04 | Tela Innovations, Inc. | Dynamic array architecture |
US8653857B2 (en) | 2006-03-09 | 2014-02-18 | Tela Innovations, Inc. | Circuitry and layouts for XOR and XNOR logic |
US7956421B2 (en) | 2008-03-13 | 2011-06-07 | Tela Innovations, Inc. | Cross-coupled transistor layouts in restricted gate level layout architecture |
US8658542B2 (en) | 2006-03-09 | 2014-02-25 | Tela Innovations, Inc. | Coarse grid design methods and structures |
US7577049B1 (en) | 2006-08-08 | 2009-08-18 | Tela Innovations, Inc. | Speculative sense enable tuning apparatus and associated methods |
US8286107B2 (en) | 2007-02-20 | 2012-10-09 | Tela Innovations, Inc. | Methods and systems for process compensation technique acceleration |
US7979829B2 (en) * | 2007-02-20 | 2011-07-12 | Tela Innovations, Inc. | Integrated circuit cell library with cell-level process compensation technique (PCT) application and associated methods |
US8667443B2 (en) | 2007-03-05 | 2014-03-04 | Tela Innovations, Inc. | Integrated circuit cell library for multiple patterning |
NZ583783A (en) * | 2007-09-20 | 2012-10-26 | Commw Scient Ind Res Org | Avian interferon-lambda polypeptide and genetic sequences encoding the same |
BRPI0818039A2 (pt) * | 2007-10-15 | 2014-10-14 | Chugai Pharmaceutical Co Ltd | Método para produzir uma célula capaz de produção de alto rendimento de heteroproteínas. |
US8453094B2 (en) | 2008-01-31 | 2013-05-28 | Tela Innovations, Inc. | Enforcement of semiconductor structure regularity for localized transistors and interconnect |
US7939443B2 (en) | 2008-03-27 | 2011-05-10 | Tela Innovations, Inc. | Methods for multi-wire routing and apparatus implementing same |
SG192532A1 (en) | 2008-07-16 | 2013-08-30 | Tela Innovations Inc | Methods for cell phasing and placement in dynamic array architecture and implementation of the same |
US9122832B2 (en) | 2008-08-01 | 2015-09-01 | Tela Innovations, Inc. | Methods for controlling microloading variation in semiconductor wafer layout and fabrication |
GB0820631D0 (en) * | 2008-11-11 | 2008-12-17 | London School Hygiene & Tropical Medicine | Vectors |
EP2239322A1 (fr) * | 2009-04-07 | 2010-10-13 | Basf Se | Utilisation d'enzymes pour réduire le formaldéhyde dans des produits contenant du formaldéhyde |
US8661392B2 (en) | 2009-10-13 | 2014-02-25 | Tela Innovations, Inc. | Methods for cell boundary encroachment and layouts implementing the Same |
US9159627B2 (en) | 2010-11-12 | 2015-10-13 | Tela Innovations, Inc. | Methods for linewidth modification and apparatus implementing the same |
EP2740485B1 (fr) | 2012-12-07 | 2018-10-31 | Brightpulse Holding LTD. | Protéine slurp-1 pour l'utilisation dans le traitement des maladies oculaires |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4359415A (en) * | 1981-06-03 | 1982-11-16 | University Of Tennessee Research Corporation | Isolation of an antineoplastic protein fraction and an antineoplastic peptide fraction from human urine |
US4470970A (en) * | 1981-07-02 | 1984-09-11 | Burzynski Stanislaw R | Purified antineoplaston fractions and methods of treating neoplastic disease |
US5298604A (en) * | 1992-07-27 | 1994-03-29 | Sloane Nathan H | Parital primary amino acid sequence of the antineoplastic protein (ANUP); a cytokine present in granulocytes |
-
1992
- 1992-12-22 IT ITRM920919A patent/IT1257184B/it active IP Right Grant
-
1993
- 1993-12-21 UA UA95062918A patent/UA46702C2/uk unknown
- 1993-12-21 AU AU58335/94A patent/AU690093B2/en not_active Ceased
- 1993-12-21 DE DE69332861T patent/DE69332861T2/de not_active Expired - Fee Related
- 1993-12-21 PT PT94904167T patent/PT675956E/pt unknown
- 1993-12-21 DK DK94904167T patent/DK0675956T3/da active
- 1993-12-21 KR KR1019950702407A patent/KR100193107B1/ko not_active IP Right Cessation
- 1993-12-21 JP JP6514813A patent/JP3025014B2/ja not_active Expired - Fee Related
- 1993-12-21 AT AT94904167T patent/ATE236976T1/de not_active IP Right Cessation
- 1993-12-21 US US08/448,561 patent/US5908827A/en not_active Expired - Fee Related
- 1993-12-21 CA CA002151156A patent/CA2151156A1/fr not_active Abandoned
- 1993-12-21 ES ES94904167T patent/ES2193152T3/es not_active Expired - Lifetime
- 1993-12-21 EP EP94904167A patent/EP0675956B1/fr not_active Expired - Lifetime
- 1993-12-21 WO PCT/EP1993/003645 patent/WO1994014959A1/fr active IP Right Grant
- 1993-12-22 IL IL10814993A patent/IL108149A/xx not_active IP Right Cessation
- 1993-12-22 RU RU95113418/13A patent/RU2177480C2/ru not_active IP Right Cessation
- 1993-12-22 ZA ZA939621A patent/ZA939621B/xx unknown
-
1995
- 1995-06-21 FI FI953091A patent/FI114478B/fi active IP Right Grant
- 1995-06-21 NO NO19952494A patent/NO315800B1/no not_active IP Right Cessation
-
2004
- 2004-04-29 FI FI20040608A patent/FI116059B/fi active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
UA46702C2 (uk) | 2002-06-17 |
EP0675956A1 (fr) | 1995-10-11 |
KR950704486A (ko) | 1995-11-20 |
FI953091A0 (fi) | 1995-06-21 |
NO952494L (no) | 1995-08-21 |
ITRM920919A0 (it) | 1992-12-22 |
ATE236976T1 (de) | 2003-04-15 |
ITRM920919A1 (it) | 1994-06-22 |
NO315800B1 (no) | 2003-10-27 |
IL108149A (en) | 2005-05-17 |
DK0675956T3 (da) | 2003-07-07 |
ES2193152T3 (es) | 2003-11-01 |
FI116059B (fi) | 2005-09-15 |
KR100193107B1 (ko) | 1999-06-15 |
EP0675956B1 (fr) | 2003-04-09 |
IL108149A0 (en) | 1994-04-12 |
RU2177480C2 (ru) | 2001-12-27 |
AU690093B2 (en) | 1998-04-23 |
WO1994014959A1 (fr) | 1994-07-07 |
NO952494D0 (no) | 1995-06-21 |
FI953091A (fi) | 1995-06-21 |
DE69332861D1 (de) | 2003-05-15 |
JPH08509359A (ja) | 1996-10-08 |
FI20040608A (fi) | 2004-04-29 |
CA2151156A1 (fr) | 1994-07-07 |
US5908827A (en) | 1999-06-01 |
JP3025014B2 (ja) | 2000-03-27 |
IT1257184B (it) | 1996-01-10 |
DE69332861T2 (de) | 2004-01-29 |
FI114478B (fi) | 2004-10-29 |
AU5833594A (en) | 1994-07-19 |
PT675956E (pt) | 2003-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA939621B (en) | Protein named component B | |
HK1002017A1 (en) | Lyospheres comprising gonadotropin | |
GB9201857D0 (en) | Novel compound | |
ES2193144T3 (es) | Compuestos de dna que comprenden secuencias que codifican manuronano c-5-epimerasa. | |
DK0687260T3 (da) | Fremgangsmåde til fremstillingen af 9-desoxotaxaner | |
ES2131528T3 (es) | Nuevos polipeptidos y su uso. | |
PL319829A1 (en) | Crystallisation of laevobupivacaine and its analoques | |
DK455088D0 (da) | Syntetiske receptoranaloger | |
IL122606A (en) | (S)-hydroxa-nitrile-lyase | |
AU4876196A (en) | A process for the preparation of factor ix from biological sources | |
DK0670837T3 (fr) | ||
PL331942A1 (en) | Method of biologically transforming colchicinoid compounds into their correcponding 3-glycoside derivatives | |
DK0717744T3 (da) | Fremgangsmåde til fremstilling af 9-(-2-hydroxy)-ethoxymethylguanin | |
KR950700988A (ko) | 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof) | |
AU3384495A (en) | Or-1 on orphan receptor belonging to the nuclear receptor family | |
DK0937094T3 (da) | Fremgangsmåde til fremstilling af ivermectin | |
DK0454739T3 (da) | Fremgangsmåde til isolering af oprenset EPI protein fra en opløsning, især en fermenteringsopløsning | |
HK1013656A1 (en) | A process for the purification of natural pulmonary surfactant material using supercritical fluids | |
DE59611353D1 (de) | Transketolase-verwandtes protein | |
CZ145095A3 (en) | Novel triazoloquinazolines, process of their preparation and use | |
IL98850A0 (en) | Pristinamycin derivative and its preparation | |
AU6661394A (en) | Purification of fluoronucleosides |